首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3472256篇
  免费   295625篇
  国内免费   13344篇
耳鼻咽喉   47507篇
儿科学   110459篇
妇产科学   90318篇
基础医学   553518篇
口腔科学   94014篇
临床医学   319320篇
内科学   613842篇
皮肤病学   91828篇
神经病学   297098篇
特种医学   135484篇
外国民族医学   295篇
外科学   530032篇
综合类   103358篇
现状与发展   24篇
一般理论   2408篇
预防医学   300091篇
眼科学   79102篇
药学   238778篇
  26篇
中国医学   9380篇
肿瘤学   164343篇
  2021年   55092篇
  2020年   35123篇
  2019年   58095篇
  2018年   71524篇
  2017年   54536篇
  2016年   59944篇
  2015年   74093篇
  2014年   108222篇
  2013年   173442篇
  2012年   95857篇
  2011年   96729篇
  2010年   117433篇
  2009年   121656篇
  2008年   83594篇
  2007年   87445篇
  2006年   97151篇
  2005年   92942篇
  2004年   94471篇
  2003年   84996篇
  2002年   74826篇
  2001年   104221篇
  2000年   96988篇
  1999年   96766篇
  1998年   64917篇
  1997年   62859篇
  1996年   61031篇
  1995年   56431篇
  1994年   50702篇
  1993年   47347篇
  1992年   68839篇
  1991年   66069篇
  1990年   62633篇
  1989年   61746篇
  1988年   57562篇
  1987年   56319篇
  1986年   53674篇
  1985年   53254篇
  1984年   48969篇
  1983年   45041篇
  1982年   42066篇
  1981年   39712篇
  1980年   37396篇
  1979年   41393篇
  1978年   36730篇
  1977年   33272篇
  1976年   30536篇
  1975年   29406篇
  1974年   31009篇
  1973年   30074篇
  1972年   28295篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
931.

Background

Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.

Patients and Methods

We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.

Results

Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.

Conclusions

FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients.  相似文献   
932.
Maternal and Child Health Journal - Background Prenatal substance use screening is recommended. The 4 P’s Plus screener includes questions on perceived problematic substance use in parents...  相似文献   
933.
934.
935.
ObjectiveClinical specialty societies recommend long-acting reversible contraceptives (LARCs) as first-line contraception for adolescent women. We evaluated whether a combined educational and process improvement intervention enhanced LARC placement in primary care within an integrated health care system.MethodsThe intervention included journal clubs, live continuing education, point-of-care guidelines, and new patient materials. We conducted a retrospective cohort study across 3 time periods: baseline (January 2013?September 2015), early implementation (October 2015–March 2016), and full implementation (April 2016–June 2017). The primary outcome was the proportion of LARCs placed by primary care clinicians among women aged 13 to 18 years compared with gynecology clinicians.ResultsKaiser Foundation Health Plan of Colorado cared for approximately 20,000 women aged 13 to 18 years in each calendar quarter between 2013 and 2017. Overall, LARC placement increased from 7.0 per 1000 members per quarter at baseline to 13.0 per 1000 during the full intervention. Primary care clinicians placed 6.2% of all LARCs in 2013, increasing to 32.1% by 2017 (P < .001), including 45.5% of contraceptive implants. Clinicians who attended educational sessions were more likely to adopt LARCs than those who did not (17.9% vs 6.4% respectively, P = .009). Neither overall LARC placement rates (relative risk, 1.9; 95% confidence interval, 0.7?5.6) nor contraceptive implant rates (relative risk, 3.0; 95% confidence interval, 0.9?9.8) increased significantly in clinicians who attended educational activities.ConclusionsThis multimodal intervention was associated with increased LARC placement for adolescent women in primary care. The combination of education and process improvement is a promising strategy to promote clinician behavior change.  相似文献   
936.
937.
938.
939.
940.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号